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AbsTrACT
Objectives to evaluate the long-term efficacy and 
safety of canakinumab in patients with active systemic 
juvenile idiopathic arthritis (JIA).
Methods patients (2–19 years) entered two phase 
III studies and continued in the long-term extension 
(LtE) study. Efficacy assessments were performed 
every 3 months, including adapted JIA American 
College of rheumatology (aJIA-ACr) criteria, Juvenile 
Arthritis disease Activity Score (JAdAS) and ACr 
clinical remission on medication criteria (CrACr). 
Efficacy analyses are reported as per the intent-to-treat 
population.
results 144 of the 177 patients (81%) enrolled in 
the core study entered the LtE. overall, 75 patients 
(42%) completed and 102 (58%) discontinued 
mainly for inefficacy (63/102, 62%), with higher 
discontinuation rates noted in the late responders 
group (n=25/31, 81%) versus early responders 
(n=11/38, 29%). At 2 years, aJIA-ACr 50/70/90 
response rates were 62%, 61% and 54%, respectively. 
CrACr was achieved by 20% of patients at month 6; 
32% at 2 years. A JAdAS low disease activity score 
was achieved by 49% of patients at 2 years. Efficacy 
results were maintained up to 5 years. of the 128/177 
(72.3%) patients on glucocorticoids, 20 (15.6%) 
discontinued and 28 (22%) tapered to 0.150 mg/kg/
day. Seven patients discontinued canakinumab due to 
Cr. there were 13 macrophage activation syndrome 
(three previously reported) and no additional deaths 
(three previously reported). no new safety findings 
were observed.
Conclusion response to canakinumab treatment 
was sustained and associated with substantial 
glucocorticoid dose reduction or discontinuation and 
a relatively low retention-on-treatment rate. no new 
safety findings were observed on long-term use of 
canakinumab.
Trial registration numbers nCt00886769, 
nCt00889863, nCt00426218 and nCt00891046.
InTrOduCTIOn
Currently available therapies for systemic juvenile 
idiopathic arthritis (sJIA) include non-steroidal 
Key messages
What is already known about this subject?
 ► The key role of IL1 in the pathogenesis of 
sJIA and the therapeutic implications from its 
blocade.
 ► Canakinumab, a fully human monoclonal Ab 
which selectively blocks IL1 beta in patients 
with sJIA, has proved its efficacy and safety 
during a phase II and phase III clinical program.
What does this study add?
 ► The study provides with long term (up to 5 
years) safety and drug survival data on a 
pooled population from canakinumab’s clinical 
program. Canakinumab’s effect on systemic 
features and joints proved to be maintained 
in the long term particularly in the early 
responders patients. For the first time early 
response has been shown to be linked to 
canakinumab’s long term survival rendering it 
as an easy identifiable clinical predictor factor 
of long term maintenace of remission/low 
disease activity.
How might this impact on clinical practice or 
future developments?
 ► As long as achievement, as much as 
maintenance of remission or alternatively 
low disease activity constitute the ultimate 
therapeutic target in order to prevent 
future organ damages and disease related 
comorbidities, time to response will facilitate 
physicians in their decision making to keep or 
switch canakinumab to another treatment in a 
timely manner.
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anti-inflammatory drugs, glucocorticoids, synthetic disease-mod-
ifying antirheumatic drugs (DMARD) and biologic DMARDs 
that inhibit primarily interleukin (IL)-6 and IL-11–7; tumour 
necrosis factor blockers and CTL4-Ig for sJIA without systemic 
features.8–13 Management of sJIA is aimed at achieving and 
maintaining clinical remission (CR). Minimising glucocorti-
coid exposure, ideally up to discontinuation, is also of foremost 
importance in an effort to prevent the inhibition of growth.14 15
IL-1 plays a key role in the pathogenesis of sJIA.16 Several 
reports have suggested that inhibition of IL-1 provides clin-
ical benefit in sJIA.1 17 Canakinumab is a fully human mono-
clonal antibody that selectively binds to IL-1β, inactivating its 
downstream signalling cascade. Previous phase II–III trials have 
demonstrated the efficacy and safety of canakinumab in patients 
with sJIA.4 5
Here, we report the long-term efficacy and safety of canak-
inumab in patients with sJIA with active systemic features and 
arthritis at baseline, who were enrolled from the previously 
reported pivotal phase III studies,5 and followed for up to 5 
years.
MeTHOds
study design
The study design of the two pivotal phase III trials has been previ-
ously reported.5 Briefly, in trial 1 of 1-month duration, a single 
canakinumab dose or placebo was administered. Patients from trial 
1 could enter the two-part trial 2 where canakinumab-naïve patients 
and patients from a phase II trial4 were additionally enrolled. Trial 
2 was a randomised withdrawal study,18 with an open-label lead 
in part I up to 32 weeks. Glucocorticoid tapering was permitted, 
and monitored by the Paediatric Rheumatology International 
Trials Organisation (PRINTO) and the Pediatric Rheumatology 
Collaborative Study Group (PRCSG) coordinating centres,19 based 
on disease activity level5 (achieved at least an American College 
of Rheumatology (ACR) 50 with no fever and C-reactive protein 
(CRP) <10 mg/L; further details in (online supplementary file 1). 
Part I of trial 2 was followed by a randomised, double-blind, place-
bo-controlled, event-driven withdrawal part II in which adapted 
JIA American College of Rheumatology (aJIA-ACR) 30 responders 
able to taper/discontinue glucocorticoids were randomised to 
receive placebo or continue canakinumab until the end of trial 2 
or a flare of sJIA had occurred (part II; average total study dura-
tion of 29.5 weeks).20 Patients from trial 2 (figure 1) were allowed 
to enter the open-label, long-term extension (LTE) study where 
patients were planned to be followed for a minimum of 96 weeks, 
with further glucocorticoid tapering as per physician’s decision. 
Patients received canakinumab 4 mg/kg subcutaneously every 4 
weeks (maximum dose: 300 mg); canakinumab dose was tapered 
in the LTE to 2 mg/kg every 4 weeks in patients who were gluco-
corticoid free as per physicians’ judgement.
Patients
Patients were followed up in the LTE study between 6 July 2009 
and 5 December 2014 at 63 centres of PRINTO/PRCSG in 21 
countries. Eligibility criteria for the phase III trials have been 
described previously.5 In brief, eligible children (2–19 years old) 
with confirmed sJIA as per the International League Against 
Rheumatism classification criteria, active systemic features of 
sJIA, at least two active joints, CRP level >30 mg/L (normal 
range: 0–10 mg/L) and being treated with a prednisone equiva-
lent of ≤1.0 mg/kg/day were included. Major exclusion criteria 
included macrophage activation syndrome (MAS) within the last 
6 months, active infections, malignancies and concurrent use of 
other biologics.
Assessments
Efficacy assessments were performed at least every 3 months to 
assess the levels of improvement using various composite vali-
dated measures: aJIA-ACR 50/70/90, based on the JIA core set 
variables,21–24 plus the absence of fever (defined as temperature 
≤38°C in the preceding 7 days); clinically inactive disease (CID)/
clinical remission on medication (CR), defined as at least 6 
months of CID, which were evaluated by either the ACR criteria 
(CIDACR/CRACR)
25 26 or by the Juvenile Arthritis Disease Activity 
Score 71-CRP (JADAS; CIDJADAS/CRJADAS).
27 Disease activity was 
measured by JADAS score with the following cut-offs: CIDJADAS 
score ≤1; low disease activity (LDA) score ≤3.8; moderate 
disease activity score 3.9–10.5; and high disease activity (HDA) 
score >10.527–29; systemic features were reflected in the physi-
cian global evaluation of disease activity measured on a visual 
analogue scale.
Safety and tolerability of canakinumab were assessed in terms 
of adverse events (AE), serious AEs (SAE) and clinical and labo-
ratory assessments from first injection until the last available 
observation. Serious infections, malignancies and cases of MAS 
were adjudicated by independent committees.30–33
A three-tiered approach was used to measure anti-canaki-
numab antibodies (anti-drug antibody (ADAs)), consisting of 
a screening, a confirmatory and a titration assay, respectively. 
Serum canakinumab concentrations (pharmacokinetics, PK) 
were determined to assess the relationships between canaki-
numab exposure and the immunogenicity data.34 35
statistical analysis
The European League Against Rheumatism (EULAR) recom-
mendation for reporting LTE studies36 and the Consolidated 
Standards of Reporting Trials statement37 38 were followed. 
Categorical variables were summarised by absolute frequencies 
and percentages, while continuous variables were summarised 
by median and lower and upper quartiles. The aJIA-ACR criteria 
used the starting day of canakinumab as baseline. Efficacy anal-
yses were performed in two ways: (1) for primary analysis: in 
the intent-to-treat (ITT) population based on observed data with 
all discontinuations at different time points counted as missing 
(n=177; patients enrolled in trial 2) and (2) with missing data 
imputed using last observation carried forward (LOCF) (online 
supplementary appendix).39
In exploratory analysis, the hypothesis was tested that early 
responders achieve more substantial sJIA control as compared 
with late responders of canakinumab. For the purpose of this 
analysis, early responders were defined as patients who had 
successfully completed the glucocorticoid tapering in part I of 
trial 2 as per protocol and who were randomised to the with-
drawal part; late responders were defined as patients who moved 
directly from the open-label part of trial 2 because they failed to 
taper glucocorticoids in part I. Mixed model analyses were used 
to quantify the difference in efficacy responses for early and late 
responders. Subgroup exploratory analyses were also consid-
ered by methotrexate (MTX) coadministration and prior use 
of biologics using the generalised mixed model framework. All 
mixed models were adjusted for repeated measures, and include 
a centre-related random effect and the following covariates: 
time in study, prior use of biologics, prior use of MTX, prior 
use of corticosteroid, number of joints with limitation of motion 
(LOM) and number of active joints.
AEs were summarised by presenting the number of events and 
percentage of patients and time-adjusted frequencies of expo-
sure as per the primary system organ class based on the Medical 
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Figure 1 Flow chart with patient disposition. *One death occurred during part I; patient died due to MAS. †A patient in the placebo group died due 
to MAS 2 days after discontinuing the part II phase due to MAS. ‡One patient died from disease progression 3 months after discontinuation from the 
long-term extension phase due to unsatisfactory therapeutic effect. The grey box represents the patients who discontinued the part I or part II of trial 
2 and entered the long-term extension study. Patients who entered the LTE are divided into two subgroups: (1) early responders, defined as patients 
who had successfully completed the glucocorticoid tapering in part I of trial 2 as per protocol and who were randomised to the withdrawal part; (2) 
late responders, defined as patients who moved directly from the open-label part of trial 2 and who failed to taper glucocorticoids in part I. LTE, long-
term extension; MAS, macrophage activation syndrome.
Dictionary for Regulatory Activities (MedDRA, Version 17.1) 
preferred term.
resulTs
baseline characteristics and patient disposition over time
Demographics and baseline disease characteristics of the 177 
patients at baseline as well as the 144 patients rolling over to 
the LTE study are presented in table 1. At baseline, as previously 
reported, 99.4% of patients had HDA (median JADAS=32.5).
Of the 177 patients (per ITT, denominator is 177 unless other-
wise stated) enrolled in trial 2, a total of 144 (81%) continued 
in the LTE study (figure 1); 122 (69%) stayed for a maximum of 
271 weeks. Overall, 75 (42%) patients completed the LTE study.
As shown in table 1, among the 144 patients who entered LTE, 
there were 96 (54.2%) early responders with a median JADAS 
of 1.85 denoting an LDA status (62% JADAS LDA and 47.9% 
CIDJADAS) at baseline of the LTE study, and 48 (27.1%) late 
responders with a median JADAS of 18.8 denoting HDA status 
(69% with JADAS HDA at baseline of the LTE). Compared with 
early responders, the late group had a higher frequency of prior 
use of biologics (79.2% vs 57.3%) and required higher gluco-
corticoid doses (0.36 mg/kg/day vs 0.17 mg/kg/day). Similar 
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Table 1 Demographics and clinical characteristics of patients at baseline (date of first canakinumab administration and at the time of entry into 
the LTE study)
Characteristics
baseline lTe study*
early responders (lTe study 
entry data)*
late responders (lTe study 
entry data)*
(n=177†) (n=144†) (n=96†) (n=48†)
Female 98 (55%) 79 (55%) 53 (55%) 26 (54%)
Age (years) 8.0 (5.0–12.0) 9.0 (6.0–13.0) 9.0 (6.0–13.0) 9.0 (5.5–11.5)
Body weight (kg) n=167
25.8 (17.8–42.9)
n=142
29.6 (20.1–46.0)
n=94
31.4 (21.0–51.2)
26.3 (18.1–38.5)
Disease duration (years) n=124
2.1 (0.8–4.3)
n=101
2.3 (0.9–4.4)
n=71
2.1 (0.8–4.3)
n=30
2.8 (1.3–4.8)
Physician’s global assessment of disease activity (VAS) (mm) 70.0 (55–80) 7.0 (0–33.0) 1.0 (0–19.0) 29.0 (9.5–47.5)
Parent or patient’s assessment of overall well-being (VAS) 
(mm)
n=176
63.5 (45.0–80.0)
6.0 (1.0–44.5) 2.0 (0–26.5) 29.0 (8.0–52.0)
Number of joints with active arthritis‡ 10.0 (4.0–22.0) 1.0 (0–5.0) 0 (0–2.5) 3.5 (1.5–12.5)
Number of joints with limited range of motion§ 9.0 (4.0–23.0) 1.5 (0–5.0) 0 (0–3.0) 5.0 (1.5–15.5)
CHAQ score 1.8 (1.1–2.3) 0.3 (0–1.1) 0 (0–0.9) 0.8 (0.2–1.6)
C-reactive protein (mg/L) 160.0 (88–271.0) 16.0 (3.30–87.6) 6.6 (2.0–42.5) 83.1 (22.8–133.2)
Fever 161 (91%) 25 (17.4%) 11 (11.5%) 14 (29.2%)
JADAS score n=176
32.5 (26.0–43.3)
7.85 (0.3–19.6) 1.85 (0.1–12.2) 18.85 (8.2–28.3)
JADAS high disease activity (>10.5) 175 (99.4%) 63 (43.8%) 30 (31.3%) 33 (68.8%)
JADAS low disease activity (≤3.8) 0 67 (46.5%) 59 (61.5%) 8 (16.7%)
JADAS CID (≤1) 0 48 (33.3%) 46 (47.9%) 2 (4.2%)
Use of methotrexate at baseline 94 (53%) 76 (52.8%) 49 (51.0%) 27 (56.3%)
Prior use of biologics¶ 116 (66%) 93 (64.6%)** 55 (57.3%) 38 (79.2%)
  Anakinra 83 (47%) 65 (45.1%)** 44 (45.8%) 21 (43.8%)
  Tocilizumab 10 (6%) 7 (4.9%)** 5 (5.2%) 2 (4.2%)
  Anti-TNF agent or other biologic agent 62 (35%) 50 (34.7%)** 25 (26.0%) 25 (52.1%)
Prednisone therapy at baseline 128 (72%) 63 (43.8%) 20 (20.8%) 43 (89.6%)
Prednisone equivalent dose†† (mg/kg/day) n=128
0.27 (0.17–0.54)
n=63
0.23 (0.16–0.49)‡‡
n=20
0.17 (0.08–0.20)
n=43
0.36 (0.21–0.55)
Data are n (%) or medians (first to third quartiles).
Patients entering the LTE are divided into those coming from the double-blind placebo-controlled withdrawal part (early responders who were patients randomised in the 
withdrawal part) or from the open-label part of trial 2 (late responders who failed to achieve an adapted juvenile idiopathic arthritis American College of Rheumatology (aJIA-
ACR) 30 response or to taper glucocorticoids in part I).
*Baseline characteristics are carried forward from last non-missing values of previous study.
†n is indicated in the rows only if the total number is different from the heading column.
‡The range of possible values for number of joints with active arthritis was 0–73.
§The range of possible values for number of joints with limited range of motion was 0–69.
¶A patient could have received one or more biologic agents previously.
**Patients were not allowed to take any biologics during treatment. These were patients with prior use of biologics before the core study.
††Median dose provided for the patients who were on steroids at study entry.
‡‡Median dose of the subgroups from part I and part II with great difference in the median steroid doses as demonstrated in the adjacent columns.
CHAQ, Childhood Health Assessment Questionnaire; CID, clinically inactive disease; JADAS, Juvenile Arthritis Disease Activity Score; LTE, long-term extension; n, number of 
observations; TNF, tumour necrosis factor; VAS, visual analogue scale.
differences were noted at baseline (day of the first canakinumab 
administration) in the two groups.
A total of 102 (58%) patients discontinued canakinumab: 
33 during trial 2 as previously reported5 and the remaining 
69 during the LTE study. Non-response (n=26/102, 25%) and 
loss of response over time (n=36/102, 35%) were the main 
reasons for discontinuation with majority coming from the late 
responders group (n=25/36, 69%), followed by intolerance 
(n=19/102, 19%). Seven patients (n=7/102, 7%) discontinued 
canakinumab as per the physicians’/family decision no longer 
requiring canakinumab.
Canakinumab tapering/discontinuation
Forty-four (25%) patients received at least three consecutive 
reduced doses of canakinumab of 2 mg/kg. Of these, 26 (59%) 
remained on a sustained reduced dose until study end with a 
median time of follow-up of 25 months. Of these 26 patients, 
five discontinued canakinumab (no longer requiring study drug) 
and two discontinued the study (consent withdrawal, n=1; 
lymphadenitis, n=1). Conversely, of the remaining 18 patients 
who flared after tapering of canakinumab, 15 regained sJIA 
control on uptitration of canakinumab to 4 mg/kg/month while 
three patients did not. In two of those patients disease flare was 
associated with MAS.
sJIA disease control and response to canakinumab
Figure 2 shows the change in JADAS score over time in the 
ITT population for the two major subgroups (early and late 
responders) who entered the LTE from part I and part II of trial 
2.
For the patients who entered the LTE from the open-label part 
of trial 2 (n=48), a decrease in disease activity by a median of 
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Figure 2 JADAS scores over time in the ITT population for the two major subgroups (early and late responders) who entered the LTE from part I 
and part II of trial 2 (observed data). n denotes the number of patients available at that time point; horizontal lines represent the cut-offs for JADAS 
HDA>10.5, LDA≤3.8 and ID≤1. Denominator is equal to 177 patients per the ITT principle. The upper and lower error bars represent the third (q3) 
and first (q1) quartiles, respectively. Patients who entered the LTE are divided into two subgroups: (1) early responders, defined as patients who 
had successfully completed the glucocorticoid tapering in part I of trial 2 as per protocol and who were randomised to the withdrawal part; (2) late 
responders, defined as patients who moved directly from the open-label part of trial 2 and who failed to taper glucocorticoids in part I. All patients 
who belonged to the full analysis set in trial 2 were taken into account. Only the last available assessment within the given interval was taken into 
account. Only patients with a value at both BSL and the respective post-BSL time point were included. BSL, baseline; CRP, C-reactive protein; HDA, 
high disease activity; ID, inactive disease; ITT, intent-to-treat; JADAS, Juvenile Arthritis Disease Activity Score; LDA, low disease activity.
64.6% (n=48) (median change: −24.9 (Q1 −32.7; Q3 −14.9)) 
and 93.5% (n=25) (median change: −31.8 (Q1 −40.3; Q3 
−24.8)) was observed within the 6 months and 2 years of canak-
inumab treatment, respectively. However, despite improvement 
on canakinumab, this group of patients continued to remain in 
JADAS HDA status (JADAS >10.5).
Early responders (n=96) achieved a greater decrease in the 
JADAS during the study as compared with late responders (mixed 
model; p<0.01). Notably, in early responders, JADAS improve-
ment by a median of 96.4% (n=95) (median change: −25.1 
(Q1 −33.1; Q3 −20.2)) occurred within the first 6 months of 
canakinumab initiation, and was maintained over at least 2 years 
(median decrease of 99.2%, n=87) (median change: −27.6 (Q1 
−34.3; Q3 −20.6) at 2 years). Overall, from the entire cohort, 
a total of 79/177 (44.6%) achieved JADAS-LDA/inactive disease 
(ID) over the first 6 months of canakinumab exposure which 
increased to 48.6% at 2 years and was sustained until the end 
of the study.
As shown in figure 3, aJIA-ACR 50/70/90 response rates in 
the ITT population at 6 months since initiation of canakinumab 
were 73.4%, 65.5% and 52.0%, respectively. This level of 
response was maintained up to 3 years with 54.8%, 53.7% and 
49.7% of the patients achieving aJIA-ACR 50/70/90 response 
rates, respectively. ClDACR since initiation of canakinumab was 
achieved by 32.8% of patients at 6 months, which increased up 
to 39.5% at 2 years and maintained through (36.7%) at year 3 
and progressively decreased to 12.4% in 5 years. The CIDJADAS 
criteria use yielded similar results.
As per figure 3, CRACR criteria were achieved by 18.6% 
(33/177) of patients within the first 6 months of canakinumab 
therapy. In these 33 early responding patients, CRACR was reached 
at a median time of 29 days. The number of patients reaching 
CRACR further increased to 31.6% after 24 months. During the 
first 2 years, 71 patients had achieved CRACR on canakinumab 
with the median time to CR being 213 days. During the study, 80 
patients had achieved CRACR (median time=254 days). Consis-
tently similar rates were observed based on CRJADAS (rates are 
shown in figure 3).
Efficacy analyses were also performed by means of LOCF. 
(online supplementary figures S1 and S2) show the corre-
sponding LOCF data confirming a trend towards higher level of 
response over time.
differences between the ITT and lOCF analyses
Both ITT and LOCF analyses were conducted for the entire 
study duration of 5 years and showed about 30%–40% 
achieving ID at year 3, the overall planned study duration. 
Because the study lasted longer in some countries (until year 
5), patients who completed the study as planned at year 3 were 
counted as discontinuations in the ITT analysis. This resulted 
in the dissociation observed in the remission rates from year 
3 to year 5 between the two methods. While maintenance of 
response up to year 5 has been demonstrated using LOCF, 
remission percentages started fading from year 3 onwards in 
the ITT analysis.
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Figure 3 aJIA-ACR responses, CIDACR/CIDJADAS rates and clinical remission on medication rates as per CRACR or CRJADAS over time (observed data). 
n denotes the number of patients available at that time point; denominator was equal to 177 patients as per the ITT principle in the pivotal study. 
Clinical remission on medication, defined as CID (ACR or JADAS) for 6 continuous months. aJIA-ACR, adapted juvenile idiopathic arthritis by American 
(online supplementary appendix) College of Rheumatology criteria; BSL, baseline; CIDACR, clinically inactive disease by ACR criteria; CIDJADAS, clinically 
inactive disease by Juvenile Arthritis Disease Activity Score criteria; CR, clinical remission; CRACR, CR by American College of Rheumatology criteria; 
CRJADAS, CR by Juvenile Arthritis Disease Activity Score criteria; ITT, intent-to-treat.
efficacy analysis of subgroups
A more pronounced decrease in disease activity as measured 
by the JADAS scores was observed in biologic naïve patients 
compared with biologic exposed patients at 6 months (92.7% 
(n=61); median change: −23.0 (Q1 −31.3; Q3 −14.3) vs 
75.6% (n=113); median change: −23.4 (Q1 −31.8; Q3 
−16.4)) (online supplementary figure 3). Similar trends were 
observed for the aJIA-ACR response criteria and CIDACR (online 
supplementary figure 4).
Patients treated with canakinumab while on MTX background 
therapy and those treated with canakinumab alone showed 
similar JADAS and aJIA-ACR response rates and CIDACR (online 
supplementary figures S5 and S6).
Glucocorticoid tapering
Among 128/177 (72.3%) patients who were on glucocorticoids 
at the beginning of trial 2 (median dose of 0.27 mg/kg/day; Q1–
Q3: 0.16–0.53 mg/kg/day), 38/128 (29.7%), 51/128 (39.8%) 
and 20/128 (15.6%) discontinued glucocorticoid therapy by 6 
months, 2 years and 5 years of canakinumab therapy, respec-
tively. At the end of the study, 72 patients (56%) remained on 
glucocorticoid treatment at a median dose of 0.25 mg/kg/day 
(Q1–Q3: 0.16–0.46 mg/kg/day), with 28 patients (22%) having 
the dose below 0.2 mg/kg/day level.
As shown in table 1, patients who entered LTE from the 
double-blind withdrawal part were on lower dose of glucocor-
ticoids (0.17 mg/kg/day) compared with patients who moved 
from the open-label part I of trial 2 (median dose of 0.36 mg/
kg/day). Of the 38 patients who failed to discontinue glucocor-
ticoids at part I of trial 2, ten became steroid free, with another 
nine patients reaching the below 0.2 mg/kg/day level.
safety
Overall, the median duration of exposure (canakinumab and 
placebo) in the study was 3.5 years (Q1, 0.6; Q3, 4.4) corre-
sponding to 476.530 patient-years. The exposure-adjusted inci-
dence rate of AEs was 796.69/100 patient-years (table 2).
The incidence rate of SAEs was 40.68/100 patient-years. Most 
common SAEs included sJIA flare (5.24/100 patient-years), MAS 
events (histiocytosis haematophagic in MedDRA terms) and 
fever either due to infection or sJIA flare (table 3).
All MAS cases were adjudicated by an independent adjudi-
cation committee for a total of 13 events (2.726/100 patient-
years) in 12 patients leading to nine patients discontinuing the 
study. Three of these were reported earlier5 and the other 10 
MAS cases were reported as SAEs in the LTE study. One of the 
reported MAS events was complicated by pulmonary hyper-
tension and interstitial pneumonia, resulting in patient death 
in the pivotal study as previously reported,5 and another event 
was complicated by transfusion-related acute lung injury; acute 
interstitial pneumonitis, following blood transfusion products 
for MAS in the LTE study. The second event resolved and the 
patient discontinued the study. No malignancies, anaphylaxis 
or anaphylactoid reactions were reported. There were no addi-
tional deaths besides the three previously reported.5
Infections
The incidence of serious infections was 10.28/100 patient-years 
of exposure and all resolved without sequelae. Most common 
serious infections were gastroenteritis (1.05/100 patient-years), 
pneumonia (0.84/100 patient-years), and varicella, subcutaneous 
abscess, gastrointestinal viral infection, septic shock and strepto-
coccal tonsillitis (0.42/100 patient-years each).
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Table 2 Incidence rates of adverse events, by system organ class
system organ class 
n=177 rate per 100 
patient-years n (%) events
Infections and infestations 136 (76.8) 1036 217.26
Gastrointestinal disorders 99 (55.9) 513 107.58
Musculoskeletal and connective tissue 
disorders
97 (54.8) 467 97.94
Respiratory, thoracic and mediastinal 
disorders
82 (46.3) 391 82.0
General disorders and administration site 
conditions
77 (43.5) 226 47.39
Skin and subcutaneous tissue disorders 76 (42.9) 245 51.38
Nervous system disorders 61 (34.5) 223 46.77
Injury, poisoning and procedural 
complications
58 (32.8) 164 34.39
Investigations 55 (31.1) 166 34.81
Blood and lymphatic system disorders 34 (19.2) 74 15.52
Eye disorders 30 (16.9) 54 11.32
Neoplasms benign, malignant and 
unspecified* (including cysts and polyps)
24 (13.6) 29 6.08
Psychiatric disorders 21 (11.9) 29 6.08
Hepatobiliary disorders 19 (10.7) 26 5.45
Ear and labyrinth disorders 17 (9.6) 39 8.18
Immune system disorders 16 (9.0) 24 5.03
Metabolism and nutrition disorders 16 (9.0) 26 5.45
Reproductive system and breast disorders 16 (9.0) 19 3.98
Vascular disorders 12 (6.8) 21 4.40
Renal and urinary disorders 9 (5.1) 12 2.52
Cardiac disorders 8 (4.5) 11 2.31
Endocrine disorders 2 (1.1) 2 0.42
Congenital, familial and genetic disorders*† 1 (0.6) 1 0.21
Social circumstances‡ 1 (0.6) 1 0.21
N denotes the total number of patients; a patient with multiple occurrences of an 
adverse event (AE) under one category is counted only once in the AE category.
*Neoplasms reported here are benign and unspecified.
†MedDRA PT: keratosis follicular.
‡MedDRA PT: dental prosthesis.
MedDRA PT, Medical Dictionary for Regulatory Activities preferred term.
Table 3 Incidence rates of serious adverse events by preferred term 
(≥2 events)
n=177 rate per 100 
patient-yearsn (%) events
Serious adverse events 64 (36.2) 194 40.68
Preferred term
  Juvenile idiopathic arthritis 17 (9.6) 25 5.24
  Histiocytosis haematophagic (MAS)* 10 (5.6) 17 3.56
  Fever 8 (4.5) 8 1.68
  Gastroenteritis 5 (2.8) 5 1.05
  Abdominal pain 4 (2.3) 4 0.84
  Pneumonia 3 (1.7) 4 0.84
  Hepatitis 2 (1.1) 3 0.63
  Hepatic enzyme increased 3 (1.7) 3 0.63
  Septic shock 2 (1.1) 2 0.42
  Arthralgia 2 (1.1) 2 0.42
  Lymphadenopathy 2 (1.1) 2 0.42
  Gastrointestinal viral infection 2 (1.1) 2 0.42
  Subcutaneous abscess 2 (1.1) 2 0.42
  Tonsillitis streptococcal 2 (1.1) 2 0.42
  Musculoskeletal chest pain 2 (1.1) 2 0.42
  Varicella 2 (1.1) 2 0.42
  Vomiting 2 (1.1) 2 0.42
  Drug reaction with eosinophilia and 
systemic symptoms
2 (1.1) 2 0.42
  C-reactive protein increased 2 (1.1) 2 0.42
  Serum ferritin increased 2 (1.1) 2 0.42
  Paraesthesia 2 (1.1) 2 0.42
  Anxiety 2 (1.1) 2 0.42
  Traumatic fracture 2 (1.1) 2 0.42
  Rash 2 (1.1) 2 0.42
N denotes the total number of patients; serious adverse events occurring after 
pivotal study baseline are presented in this table.
*MAS: macrophage activation syndrome is the terminology used in the 
literature.30–33
There were four opportunistic infections (toxoplasmosis, cyto-
megalovirus infection, Salmonella gastroenteritis and adenovirus 
infection) in one patient, each was adjudicated as such by the 
adjudication committee; two of these events were suspected to 
be related to canakinumab by the investigator. All events were 
moderate in severity and resolved following treatment. No 
tuberculosis cases were reported.
Laboratory abnormalities
Transient neutropenia was reported in 18 patients (grade 3 
(n=17); grade 4 (n=1)). Eleven neutropenia events occurred in 
patients on MTX background and three were associated with 
mild infections (pharyngitis, molluscum contagiosum, naso-
pharyngitis and otitis media), respectively. None of the patients 
discontinued canakinumab due to neutropenia but two patients 
discontinued MTX.
Besides laboratory testing that reflect the anti-inflammatory 
effects of canakinumab, other clinical chemistry parameters 
remained largely unchanged. CRP and fibrinogen decreased 
markedly by week 2 of canakinumab therapy and low levels 
were maintained over time.
Immunogenicity
Post-treatment ADAs were detected in five patients. ADAs were all 
non-neutralising and their presence had no effect on PK of canak-
inumab; the observed trough canakinumab concentrations in pres-
ence of ADAs were comparable to those without ADAs. All but 
one of the five patients were on background treatment with MTX.
dIsCussIOn
Here, we report the long-term efficacy and safety data of canak-
inumab in patients with sJIA with active systemic features and 
arthritis enrolled in the pivotal phase III trials.5 There was a marked, 
rapid improvement of sJIA activity at 6 months, which was main-
tained for up to 5 years and allowed for the marked reduction or 
even discontinuation of glucocorticoids in the majority of patients.
Due to the long duration of the study, canakinumab efficacy 
seems best described by the level of disease control as measured 
by the JADAS. Exploratory analysis suggested that early response 
to canakinumab leads to a better long-term favourable outcome. 
As such, patients who entered the LTE study from the double-
blind, placebo-controlled part because they responded to canak-
inumab quickly and successfully tapered glucocorticoids, fared 
better than late responders, that is, patients who moved directly 
from part I of trial 2 because they failed to respond to canaki-
numab initially or were unable to taper glucocorticoids as per 
protocol. These data were further corroborated by the CR 
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data, which showed a trend towards better improvement in the 
subgroup of patients who were naïve to biologics.
Glucocorticoid discontinuation was possible for 44% of the 
patients, some rapidly and some in the long term, suggesting a 
continuous glucocorticoid tapering effect of canakinumab.
The limited therapeutic benefits of MTX in sJIA were 
confirmed by similar response rates to canakinumab irrespective 
of MTX background therapy. Thus, canakinumab/MTX combi-
nation therapy is unlikely expected to improve sJIA control 
versus using canakinumab alone.
Most children who reached CID/LDA level after canakinumab 
initiation who were randomised to placebo and flared in the double-
blinded part of trial 2 regained the LDA status on retreatment with 
canakinumab. This observation may suggest that canakinumab ther-
apeutic benefits can be recaptured after withdrawal or interruption 
of medication in children who previously responded well to canaki-
numab. Based on the time to flare in the double-blinded part of the 
study, a CID/LDA state would be expected to be maintained longer 
than the half-life of the drug. Further, these data also support that 
the withdrawal study design with an event-driven approach as was 
chosen for trial 2 did not expose children switched to placebo to 
worse long-term outcomes than children who were randomised to 
continue canakinumab.
The long-term use of canakinumab was well tolerated and 
consistent with the safety profile that has been reported in 
other canakinumab trials.5 Infections were the most common 
AEs. Despite disease control, new MAS events occurred while 
on canakinumab therapy. This is consistent with the previous 
reports,33 which suggested that canakinumab treatment does 
not seem to alter the risk of MAS in patients with sJIA, regard-
less of the response of sJIA to canakinumab. Of note, the MAS 
adjudication committee was established before the EULAR/ACR/
PRINTO MAS classification criteria were published.33
A limitation of this study may be the overall low retention 
rate with 58% of the patients discontinuing canakinumab over 
the 5 years, which is typically expected in a study with such long 
follow-up. However, LOCF was carried out in addition to the 
observed data to address this shortcoming and possible artificial 
increasing percentages of response rates over time. The higher 
discontinuation rate in the late responders group as opposed to the 
early responders group further supports the notion of early response 
being used as a predictor factor of long-term outcome by the physi-
cians when considering canakinumab change to another treatment. 
In addition, this LTE study included patients with a wide range of 
canakinumab treatment durations due to the adaptive design chosen 
for trial 2 to limit placebo and corticosteroid exposures to patients. 
To address the limitations, another cohort of sJIA is being studied, 
where canakinumab was started in patients with and without fever 
at baseline (analysis in progress). Further, a dedicated dose reduc-
tion/dose interval prolongation study in patients with sJIA who are 
canakinumab responders is ongoing (NCT02296424).
In conclusion, response to canakinumab treatment was sustained 
or improved up to 5 years in patients with sJIA with active 
systemic features and arthritis and was associated with glucocor-
ticoid discontinuation. Early response seemed to be a predictive 
factor of long-term outcome enabling physicians to incorporate in 
their decision-making the time to response in the consideration of 
changing canakinumab to another treatment. No new safety find-
ings were observed on long-term use of canakinumab.
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